Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Stoke Therapeutics, Inc.

< Previous 1 2 Next >
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Proposed Public Offering
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.